Written by: Efram Slen, Manager, Nasdaq Global Information Services
It’s a fact: we’re living longer. According to the National Institute on Aging, “the 85-and-over population is projected to increase 351% between 2010 and 2050.” That’s not a typo! And while there are certainly numerous factors that have led to the change, advancements in healthcare have been key.
Largely fueled by biotech—a merging of medicine and technology—the rate of change and innovation in healthcare is nothing short of stunning. As the industry strives to meet the mounting healthcare needs of older Baby Boomers, innovation is only expected to accelerate.
The products that are in development today are fascinating.
Surgical knives are transforming cancer treatment by laser-focusing high dose radiation to treat otherwise inoperable tumors—with no invasive surgery, no anesthesia, and no post-treatment downtime. RNA chemistries are being used to treat intractable diseases by silencing the genes that cause them. Smartphone apps are in the works that alert caregivers in the case of unusual physical activity or locations that may indicate a crisis. Another app helps emergency medical personnel more easily diagnose concussions on the spot for school-age athletes. The innovations seem endless, as do the opportunities for growth.
For investors, industry innovation often provides opportunity. When it comes to today’s healthcare innovators, they offer a few additional advantages.
- As a whole, healthcare innovators (especially biotech firms) are largely uncorrelated to the market.
- As science evolves at lightning speed, so do their products. This dynamic accelerates the development lifecycle to quickly generate new revenue streams.
- Healthcare innovators are bolstered by an aging population that is willing to pay a high price to stay healthy and happy as long as possible.
Of course, the largest opportunity exists when investing in companies that have yet to reach their potential. These “non-earners” are on the precipice of growth, five to ten steps away from coming into their own as market leaders. In the summer of 1996, a little company called Starbucks was trading for $1.50 a share (it hit a high of $62.61 last October). The following summer, newly formed Amazon was trading for $1.50 a share (it jumped over $770 earlier this month). Sure, these are every investor’s dream, but one key to the old adage of “buying low and selling high” is getting in at the “ground floor”—before prices have had a chance to catch up with revenue potential.
To leverage this opportunity, Nasdaq has created the Nasdaq US Health Care Innovators Index, the index behind the Principal Healthcare Innovators Index ETF (symbol: BTEC). True to its name, the index is focused on companies that are true innovators and offer new products and technologies that have potential for significant growth. Unlike more established players (Amgen and Pfizer, for instance) that are already in the portfolios of many investors, these stocks deliver a new level of exposure to this typically uncorrelated sector, as well as the opportunity to invest at a time when the companies’ stock prices don’t yet reflect their potential value. Even better, investing in these innovators may be the ideal way to take advantage of the latest in healthcare—even if you’re still young and healthy enough to put off using them for your own medical care for another 30 to 40 years.
Nasdaq® is a registered trademark of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
© 2016. Nasdaq, Inc. All Rights Reserved.
Why Ray Dalio Is Wrong on Capitalism
Establish That Perfect Combination and be Unforgettable
Don’t Get Stuck With a Bad Annuity
What Does Discipline Mean to You?
Can You Take a Punch?
Let Your Audience Know How Unique You Are
Things We Don’t Talk About
What a U.S. Rate Cut Could Mean for Gold Prices
A Liquid Commodity for Diamonds with Cormac Kinney
What Does It Really Take to Be an Exceptional Advisor?
Permission to Succeed10 hours ago
A Liquid Commodity for Diamonds with Cormac Kinney
Building Smarter Portfolios10 hours ago
Why Insured Municipal Bonds Make Sense Today
Advisor Marketing10 hours ago
Why You Should Treat Your Content Like Atoms in Financial Services
Development2 days ago
Do You Understand the True Value of Advice?
Advisor Marketing2 days ago
How Often Should Financial Advisors Blog?
Leadership2 days ago
The Hidden Leadership Problem with Passion
Development3 days ago
Changing Forward Means Silencing Your Inner Gremlins
Research3 days ago
Please Don’t Buy the Dip in Nvidia or Other Chip Stocks